Next 10 |
home / stock / phar / phar articles
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disea...
This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leid...
Leiden, The Netherlands, April 3, 2024: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming's management will participate ...
Initial development in PIDs with immune dysregulation linked to PI3K? signaling Phase 2 clinical trial initiation planned for 2Q 2024 Leiden, Th...
The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a ra...
U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recordi...
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 80 points on Monday. Here are some big stocks recording gains in today’s s...
Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the...
Gainers GSE Systems, Inc. (NASDAQ: GVP) shares rose 32.4% to $0.4090 in pre-market trading after falling over 3% on Thursday. Roadzen (NASDAQ: RDZ...
News, Short Squeeze, Breakout and More Instantly...
Pharming Group N.V. Company Name:
PHAR Stock Symbol:
NASDAQ Market:
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disea...
This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leid...